# Octapharma to invest EUR 21 million in multi-use facility in Springe, Germany

Octapharma confirmed a EUR 21 million investment to build a new multi-function facility in Springe, Germany, including a new production line for human normal immunoglobulin panzyga and increased capacity for human albumin albunorm. Completion is expected in 2019.

- Type: Expansion
- Announced: 2018-09-21
- Where: Springe, Germany, Germany
- Value: $24.5M (21.0M EUR)
- Starts operating: 2019
- Status: announced
- Capacity: doubling fractionation capacity to 3.6 million liters by 2020
- Products: human normal immunoglobulin panzyga, human albumin albunorm
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Octapharma](https://endata.com/companies/45434.md)

## Sources

- [octapharma.com](https://www.octapharma.com/news/corporate-news/2018/octapharma-to-build-new-multi-use-venue), 2020-02-21: "This multi-function building plays an important role for the growth strategy of Octapharma worldwide, but especially at the site in Springe, Germany, as it allows us to establish a new product line without affecting the current production."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.